| Literature DB >> 28586063 |
Huan Tian1, Shicai Chen1, Caiyun Zhang1, Meng Li1, Hongliang Zheng1.
Abstract
The present study was performed to identify the dysregulated microRNAs (miRNAs/miRs) and mRNAs, and enriched pathways involved in nasopharyngeal carcinoma (NPC) through the establishment of an miRNA‑mRNA‑pathways network. mRNA and miRNA expression profiles were collected from the European Molecular Biology Laboratory‑European Bioinformatics Institute. Differentially expressed genes and differentially expressed miRNA were selectively screened using the metaDE package. Following prediction of the risk genes and pathway pairs involved in NPC, an miRNA‑mRNA‑pathway network was constructed by merging the miRNA‑mRNA pairs, the mRNA‑pathway pairs and the mRNA‑mRNA pairs. The miRNA and mRNA biomarkers, as well as the functional pathway pairs, were identified in the network analysis, based on the topological properties of nodes in the network. Additionally, 10‑fold cross‑validation was performed to evaluate the performance of the selected risk genes and their corresponding miRNA in NPC by calculating the area under the curve (AUC). In total, 99 upregulated and 841 downregulated genes, and 192 upregulated and 26 downregulated miRNAs were identified. The miRNA‑mRNA‑pathway network was established using 403 miRNA‑mRNA pairs, including 40 miRNAs and 302 risk genes, as well as 22 prominent pathway pairs. Network analysis demonstrated that v‑myc avian myelocytomatosis viral oncogene homolog (MYC) and hsa‑miR‑423‑5p were the mRNA and miRNA signatures for NPC, respectively. The AUC of these biomarkers for NPC was 0.7568 and 0.7798, respectively. Additionally, the focal adhesion pair pathway in cancer was identified to be associated with NPC. MYC and hsa‑miR‑423‑5p have been identified to be critical biomarkers in NPC as revealed by miRNA‑mRNA‑pathway network integrated analysis, suggesting a direction for further research into the diagnosis and treatment of NPC.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28586063 PMCID: PMC5562088 DOI: 10.3892/mmr.2017.6696
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
mRNA and miRNA datasets information for NPC.
| Microarray | Microarray type | Platform | No. of NPC samples | No. of normal control samples |
|---|---|---|---|---|
| GSE12452 | mRNA | GPL570 | 31 | 10 |
| GSE13597 | mRNA | GPL96 | 25 | 3 |
| GSE34573 | mRNA | GPL570 | 15 | 3 |
| GSE53819 | mRNA | GPL6480 | 18 | 18 |
| GSE32960 | miRNA | GPL14722 | 312 | 18 |
| GSE46172 | miRNA | GPL16770 | 4 | 4 |
miRNA, microRNA; NPC, nasopharyngeal carcinoma.
Figure 1.Gene Ontology annotation of biological processes for risk genes. Vertical axis indicates the enriched BP; horizontal axis indicates the level of enrichment. BP, biological processes.
Figure 2.Kyoto Encyclopedia of Genes and Genomes enrichment analyses for risk genes. Vertical axis indicates the enriched pathways; horizontal axis indicates the level of enrichment. MAPK, mitogen-activated protein kinase.
Topological properties of 22 prominent pathways pairs in the miRNA-risk gene-pathway network.
| Pathway pair | Topological Coefficient | Average shortest path length | Betweenness centrality | Closeness centrality | Degree |
|---|---|---|---|---|---|
| Pathways in cancer _focal adhesion[ | 0.1742 | 2.8952 | 0.0268 | 0.3454 | 24 |
| Proteoglycans in cancer _pathways in cancer | 0.1854 | 2.8754 | 0.0243 | 0.3478 | 21 |
| Wnt signaling pathway _pathways in cancer | 0.2162 | 2.9207 | 0.0109 | 0.3424 | 19 |
| Epstein-barr virus infection _htlv-i infection | 0.2144 | 3.1473 | 0.0107 | 0.3177 | 17 |
| Pathways in cancer _colorectal cancer | 0.2280 | 2.9292 | 0.0068 | 0.3414 | 17 |
| Htlv-i infection _colorectal cancer | 0.2419 | 2.9688 | 0.0059 | 0.3368 | 15 |
| Viral carcinogenesis_herpes simplex infection | 0.1946 | 2.9972 | 0.0128 | 0.3336 | 15 |
| Wnt signaling pathway _colorectal cancer | 0.2637 | 2.9745 | 0.0054 | 0.3362 | 13 |
| Wnt signaling pathway _choline metabolism in cancer | 0.2876 | 3.1671 | 0.0025 | 0.3157 | 11 |
| Cell cycle _small cell lung cancer | 0.2909 | 3.0623 | 0.0026 | 0.3265 | 9 |
| Colorectal cancer _hepatitis b | 0.3575 | 3.1983 | 0.0013 | 0.3127 | 8 |
| Rap1 signaling pathway _adherens junction | 0.2609 | 3.2720 | 0.0026 | 0.3056 | 8 |
| Bladder cancer _calcium signaling pathway | 0.2912 | 3.0850 | 0.0017 | 0.3242 | 7 |
| Bladder cancer _cell cycle | 0.3544 | 3.1841 | 0.0008 | 0.3141 | 7 |
| Bladder cancer _small cell lung cancer | 0.3383 | 3.2465 | 0.0004 | 0.3080 | 7 |
| Chemokine signaling pathway _viral myocarditis | 0.2612 | 3.2238 | 0.0046 | 0.3102 | 7 |
| Ecm-receptor interaction _amoebiasis | 0.3029 | 3.3541 | 0.0014 | 0.2981 | 7 |
| P53 signaling pathway _cell cycle | 0.3794 | 3.2125 | 0.0007 | 0.3113 | 6 |
| Shigellosis _pancreatic cancer | 0.3690 | 3.2380 | 0.0010 | 0.3088 | 6 |
| NF-kappa b signaling pathway _tuberculosis | 0.3273 | 3.6232 | 0.0013 | 0.2760 | 5 |
| Salmonella infection _shigellosis | 0.4872 | 3.3399 | 0.0004 | 0.2994 | 4 |
| Bile secretion _salivary secretion | 0.5000 | 3.7960 | 0.0002 | 0.2634 | 2 |
Highest degree. HTLV-I, human T-lymphotropic virus 1; Rap1, DNA-binding protein RAP1; ECM, extracellular matrix.
Figure 3.miRNA-mRNA-pathway pair complex network. miRNA, microRNA.
Topological properties of 15 selected risk genes with highest degrees in the miRNA-risk gene-pathway network.
| Risk gene | Topological coefficient | Average shortest path length | Betweenness centrality | Closeness centrality | Degree |
|---|---|---|---|---|---|
| MYC[ | 0.0026 | 2.0741 | 0.3792 | 0.4821 | 841 |
| TP53 | 0.0031 | 2.1036 | 0.2838 | 0.4754 | 668 |
| JUN | 0.0063 | 2.2764 | 0.0923 | 0.4393 | 268 |
| EGFR | 0.0065 | 2.528 | 0.1124 | 0.3956 | 294 |
| BIRC5 | 0.0074 | 2.3675 | 0.0784 | 0.4224 | 194 |
| TBP | 0.0075 | 2.429 | 0.065 | 0.4117 | 195 |
| MAPK8 | 0.009 | 2.3637 | 0.0543 | 0.4231 | 170 |
| SKP2 | 0.01 | 2.4516 | 0.044 | 0.4079 | 156 |
| JAK2 | 0.0103 | 2.668 | 0.0513 | 0.3748 | 168 |
| FGF2 | 0.0106 | 2.5393 | 0.0467 | 0.3938 | 139 |
| RAC1 | 0.0106 | 2.8012 | 0.0708 | 0.357 | 217 |
| BCL2 | 0.0108 | 2.4651 | 0.0418 | 0.4057 | 126 |
| CDC42 | 0.0126 | 2.7745 | 0.0419 | 0.3604 | 146 |
| EZR | 0.0126 | 2.7924 | 0.0473 | 0.3581 | 133 |
| PSMD12 | 0.0245 | 2.9105 | 0.023 | 0.3436 | 125 |
Highest degree.
Prediction accuracy of 15 risk genes for NPC after 10-fold cross-validation.
| Risk gene | AUC in GSE12452 | AUC in GSE34573 | AUC in GSE53819 | AUC in GSE13597 |
|---|---|---|---|---|
| BCL2 | 0.829 | 1 | 0.5278 | 0.68 |
| BIRC5 | 0.8903 | 0.6 | 0.7901 | 0.9467 |
| CDC42 | 0.7 | 0.5778 | 0.7377 | 0.64 |
| EGFR | 0.6258 | 0.6 | 0.6975 | 0.6 |
| EZR | 0.9774 | 1 | 0.8179 | 0.7333 |
| FGF2 | 0.8548 | 0.7778 | 0.5617 | 0.8667 |
| JAK2 | 0.7806 | 0.9111 | 0.5895 | 0.68 |
| JUN | 0.6258 | 0.6444 | 0.8827 | 0.68 |
| MAPK8 | 0.8581 | 0.5556 | 0.8025 | 0.72 |
| MYC[ | 0.8645 | 0.5333 | 0.8302 | 0.8133 |
| PSMD12 | 0.8323 | 0.9778 | 0.8981 | 0.76 |
| RAC1 | 0.6226 | 0.8 | 0.8272 | 0.92 |
| SKP2 | 0.9323 | 0.6 | 0.7994 | 0.9733 |
| TBP | 0.6903 | 0.9111 | 0.5123 | 0.6267 |
| TP53 | 0.7645 | 0.6 | 0.6914 | 0.8 |
Highest degree. The performance of the selected 15 risk genes for the NPC was evaluated using the 10-fold cross-validation through calculating the area under the receiver-operating characteristic curve. AUC, area under the curve; NPC, nasopharyngeal carcinoma.
Figure 4.miRNA-mRNA-pathway pair network of MYC. Triangle indicates miRNA, circular indicates mRNA, yellow box indicates pathway pairs; red represents the up-regulated miRNAs, genes or pathway pairs. miRNA, microRNA; MYC, v-myc avian myelocytomatosis viral oncogene homolog.